Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.jbc.2021.100346 http://scihub22266oqcxt.onion/10.1016/j.jbc.2021.100346 33524396!7846482!33524396     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Biol+Chem 2021 ; 296 (ä): 100346 Nephropedia Template TP {{tp|p=33524396|t=2021. Potent mouse monoclonal antibodies that block SARS-CoV-2 infection |pdf=|usr=}}{{33524396}} gab.com Text Potent mouse monoclonal antibodies that block SARS-CoV-2 infection JO: J Biol Chem http://www.kidney.de/pget.php?&tw=1&pmid=33524396 #FOAvip Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has developed into a global pandemic since its first outbreak in the winter of 2019. An extensive investigation of SARS-CoV-2 is critical for disease control. Various recombinant monoclonal antibodies of human origin that neutralize SARS-CoV-2 infection have been isolated from convalescent patients and will be applied as therapies and prophylaxis. However, the need for dedicated monoclonal antibodies suitable for molecular pathology research is not fully addressed. Here, we produced six mouse anti-SARS-CoV-2 spike monoclonal antibodies that not only exhibit robust performance in immunoassays including western blotting, ELISA, immunofluorescence, and immunoprecipitation, but also demonstrate neutralizing activity against SARS-CoV-2 infection to VeroE6/TMPRSS2 cells. Due to their mouse origin, our monoclonal antibodies are compatible with the experimental immunoassay setups commonly used in basic molecular biology research laboratories, providing a useful tool for future research. Furthermore, in the hope of applying the antibodies of clinical setting, we determined the variable regions of the antibodies and used them to produce recombinant human/mouse chimeric antibodies. Twit Text FOAVip Potent mouse monoclonal antibodies that block SARS-CoV-2 infection ????J Biol Chem http://www.kidney.de/pget.php?&tw=1&pmid=33524396 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33524396 #FOAvip English Wikipedia <ref>{{Cite pmid|33524396}}</ref> Potent mouse monoclonal antibodies that block SARS-CoV-2 infection #MMPMID33524396 Guo Y; Kawaguchi A; Takeshita M; Sekiya T; Hirohama M; Yamashita A; Siomi H; Murano K J Biol Chem 2021[Jan]; 296 (ä): 100346 PMID33524396show ga Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has developed into a global pandemic since its first outbreak in the winter of 2019. An extensive investigation of SARS-CoV-2 is critical for disease control. Various recombinant monoclonal antibodies of human origin that neutralize SARS-CoV-2 infection have been isolated from convalescent patients and will be applied as therapies and prophylaxis. However, the need for dedicated monoclonal antibodies suitable for molecular pathology research is not fully addressed. Here, we produced six mouse anti-SARS-CoV-2 spike monoclonal antibodies that not only exhibit robust performance in immunoassays including western blotting, ELISA, immunofluorescence, and immunoprecipitation, but also demonstrate neutralizing activity against SARS-CoV-2 infection to VeroE6/TMPRSS2 cells. Due to their mouse origin, our monoclonal antibodies are compatible with the experimental immunoassay setups commonly used in basic molecular biology research laboratories, providing a useful tool for future research. Furthermore, in the hope of applying the antibodies of clinical setting, we determined the variable regions of the antibodies and used them to produce recombinant human/mouse chimeric antibodies. |Animals[MESH] |Antibodies, Monoclonal/*biosynthesis/chemistry/isolation & purification[MESH] |Antibodies, Neutralizing/*biosynthesis/chemistry/isolation & purification[MESH] |Antibodies, Viral/*biosynthesis/chemistry/isolation & purification[MESH] |Binding Sites[MESH] |COVID-19/immunology/*prevention & control/virology[MESH] |Cloning, Molecular[MESH] |Escherichia coli/genetics/metabolism[MESH] |Gene Expression[MESH] |Genetic Vectors/chemistry/metabolism[MESH] |Humans[MESH] |Mice[MESH] |Neutralization Tests[MESH] |Protein Binding[MESH] |Protein Interaction Domains and Motifs[MESH] |Protein Subunits/administration & dosage/genetics/immunology[MESH] |Recombinant Fusion Proteins/administration & dosage/genetics/immunology[MESH] |SARS-CoV-2/*genetics/immunology[MESH] |Spike Glycoprotein, Coronavirus/administration & dosage/*genetics/immunology[MESH]Potent mouse monoclonal antibodies that block SARS-CoV-2 infection (epmc).pdf DeepDyve Pubget Overpricing